Only in medical centers; anti-aging claims are not proven.
Meta-analysis: in people with traumatic brain injury, hyperbaric oxygen improved the Glasgow Coma Scale and other outcomes versus control. Heterogeneous studies; a favorable signal but to be interpreted with caution.
View the study (meta-analysis) →Review: hyperbaric oxygen therapy (100% O2 under pressure) is being explored against aging; suitable protocols (without crossing the toxic threshold) show promise in early studies (even on telomeres and senescent cells). Promising but preliminary and expensive.
View the study (study) →Cochrane (14 trials, 753 patients): hyperbaric oxygen improves late injury of irradiated tissues in the head, neck, anus and rectum: osteoradionecrosis (better mucosal coverage, RR 1.3; less dehiscence after surgery), radiation proctitis (RR 1.72; NNT 5), head and neck flaps and healing after tooth extraction in an irradiated jaw (RR 1.4; NNT 4). No benefit in neurological injury. It does not treat the cancer: it treats the after-effects of radiotherapy. There is no evidence that it stimulates tumor growth.
See the study (meta-analysis (Cochrane)) →⏱ 3 min read
Hyperbaric oxygen therapy (HBOT) consists of breathing 100 percent oxygen inside a chamber pressurized to more than 1 atmosphere absolute (typically 1.4-3.0 ATA), a medical intervention with well-established pharmacological indications for several specific clinical conditions (carbon monoxide poisoning, decompression sickness in diving, gas gangrene, air embolism, refractory wound healing especially in diabetic foot, osteoradionecrosis, others) and, in recent years, a growing application in more controversial indications such as aging, cognition, and physical performance that have generated a significant market for soft home-use hyperbaric chambers, an expansion that requires distinguishing between the indications with solid clinical support and those still under investigation.
The clinical indications of HBOT with solid clinical support and international regulatory approval are: carbon monoxide poisoning (accelerates the elimination of CO and reduces neurological sequelae); decompression sickness in divers; air embolism; Clostridium gas gangrene; myonecrosis; refractory chronic wounds, especially in diabetic foot; osteoradionecrosis after radiotherapy; severe burns; idiopathic sudden hearing loss; a few more depending on hospital protocols; these indications require hospital hyperbaric chambers with pressures of 2.0-2.8 ATA and specialized medical supervision.
In recent years, interesting studies have been published on new indications: soft tissue healing in athletes, post-concussion recovery, cognitive performance, brain aging, mild cognitive impairment, fibromyalgia, post-viral chronic fatigue syndrome; the Israeli study by Hadanny and colleagues published in 2020 with healthy older adults showed significant improvements in cognitive parameters, telomere length, and cellular senescence after a protocol of 60 HBOT sessions at 2 ATA over 3 months, preliminary data that require independent replication but that have generated sustained clinical interest in the anti-aging potential of HBOT.
The growing market for "soft" home-use hyperbaric chambers (typically 1.3 ATA, oxygen enriched to 90-95 percent or ambient air) requires careful consideration: the low pressures and less concentrated oxygen than in hospital chambers mean that the expected therapeutic effects are quantitatively smaller, protocols are not well standardized, and most of the clinical data come from studies with higher-pressure hospital chambers; these products may have a place in experimental use with reasonable expectations, but they are not equivalent to established medical HBOT.
Medical HBOT is performed in hospital chambers or specialized clinics with specific protocols (pressure, duration, frequency, and total number of sessions) adjusted to the indication; typical sessions last 60-120 minutes at pressures of 2.0-2.8 ATA; protocols for acute indications (CO poisoning, decompression) differ from protocols for chronic indications (wounds, osteoradionecrosis); costs are significant and accessibility is limited in many regions.
Safety considerations are important: absolute contraindications include untreated pneumothorax, certain severe lung conditions, and pregnancy (relative); relative contraindications include significant claustrophobia, severe obstructive lung disease, chronic otitis media, severe sinusitis, and certain eye conditions (cataract, recent eye surgery); the most frequent adverse effects are ear and sinus barotrauma (especially on descent) and transient claustrophobia; the more serious (rare) adverse effects include pulmonary oxygen toxicity with prolonged use and cerebral oxygen toxicity at very high pressures; people with pacemakers require specific evaluation; those taking certain chemotherapy drugs may have specific contraindications; the reasonable clinical stance is this: medical HBOT is an effective and well-established intervention for specific recognized indications; experimental use for emerging indications is active and has interesting preliminary data that require confirmation; soft home chambers are an option for experimental use with more modest expectations and without clinical equivalence to medical HBOT in hospital chambers.
Information, not medical advice. Scientific evidence reflects the quality of the studies.